European Review for Medical and Pharmacological Sciences

2019 Impact Factor: 3.024

5-Year Impact Factor 2.451




Articles on COVID-19 are always evaluated and published quickly.

Any contribution is important for the Scientific Community.


We would sincerely like to thank the authors, readers, editors-in-chief, editorial board members, reviewers, and all the staff who have contributed to the development of European Review for Medical and Pharmacological Sciences.

The full text of the articles can be downloaded free of charge.

Citation in:

Current Issues

Eur Rev Med Pharmacol Sci 2021; 25 (4): 2099-2108

DOI: 10.26355/eurrev_202102_25115

Real-life efficacy and safety of Ustekinumab as second- or third-line therapy in Crohn’s disease: results from a large Italian cohort study

A. Tursi, G. Mocci, A. Cuomo, L. Allegretta, G. Aragona, R. Colucci, N. Della Valle, A. Ferronato, G. Forti, F. Gaiani, M.G. Graziani, R. Lorenzetti, F. Luzza, P. Paese, A. Penna, R. Pica, S. Piergallini, G. Pranzo, S. Rodino, A. Scarcelli, C. Zampaletta, C. Cicerone, A. Cocco, G. De’ Angelis, L. Donnarumma, M. Franceschi, S. Gallina, G. Grasso, T. Larussa, I. Luppino, R. Faggiani, L. Fanigliulo, C. Pagnini, P. Perazzo, R. Sacco, L. Sebkova, S. Scorza, M. Serio, A. De Monti, M. Picchio, W. Elisei, G. Maconi